Zeenat Parween, Correspondent, India Pharma Outlook
The pharmaceutical outsourcing landscape has changed dramatically in recent years, making the search for the Right CDMO in India a far more strategic decision than ever before.
In 2026, selecting a Contract Development and Manufacturing Organization (CDMO) is no longer just about manufacturing capacity, technical expertise, or cost efficiency.
Regulatory expectations have intensified, supply chains remain vulnerable to disruption, and data integrity standards continue to evolve across global markets, increasing the importance of a strong Compliance Guide for pharmaceutical and biotech companies evaluating CDMO partnerships.
As a result, pharmaceutical and biotech companies must now evaluate CDMO partners with far greater depth than ever before.
A “clean” inspection history alone is no longer enough to determine whether a manufacturing partner is truly reliable. Regulators such as the FDA, EMA, and MHRA are increasingly focused on operational transparency, quality culture, digital traceability, and continuous compliance readiness.
Even highly experienced manufacturers can face observations during inspections. What matters most is how effectively those issues are managed, corrected, and prevented from recurring.
In this environment, companies that fail to properly assess a CDMO’s compliance maturity risk far more than operational inconvenience. Poor partner selection can lead to import alerts, delayed product launches, costly remediation programs, regulatory scrutiny, and long-term damage to commercial credibility.
The stakes are especially high for organizations operating in biologics, sterile manufacturing, cell and gene therapy, and other highly regulated segments where compliance failures can rapidly escalate into global supply chain disruptions.
Modern CDMO evaluation therefore requires a broader and more strategic approach. Sponsors must look beyond surface-level certifications and examine how a manufacturing partner operates internally, responds to risk, manages data, and maintains inspection readiness. The strongest CDMO relationships in 2026 are built not only on manufacturing capability, but also on shared accountability for quality, patient safety, and regulatory success.
Also Read: Pharma CDMOs in India & CDMO 2.0 Model: Detailed Review 2026
"India has long held the reputation of being the 'pharmacy of the world,' especially in the generic pharma segment ... However, when it comes to CDMO — the service-driven side of the pharma industry — India still plays a relatively small role on the global stage," says Dr. Abdelaziz Toumi, CEO, Lupin Manufacturing Solutions (LMS)
When evaluating a CDMO, 2026 best practices require auditing more than just a "clean" history:
One of the biggest mistakes pharmaceutical companies make when evaluating a CDMO is assuming that a facility with zero observations automatically represents the safest option. In reality, regulatory inspections are complex, and even well-managed facilities may receive findings from agencies such as the FDA, EMA, or MHRA. What separates strong CDMOs from weak ones is not the absence of past issues, but the level of transparency surrounding them.
In 2026, best practices require sponsors to request inspection records covering at least the previous three to five years. These records should include FDA Form 483 observations, Warning Letters, EMA findings, MHRA reports, and any associated corrective action documentation. A reliable CDMO should be willing to openly discuss these findings rather than avoid or minimize them.
Inspection histories reveal far more than compliance status alone. They provide insight into operational discipline, leadership accountability, and the organization’s overall quality culture. Recurring observations related to contamination control, documentation practices, environmental monitoring, or data management often indicate systemic weaknesses that may continue to create risk in the future.
Transparency has become increasingly important because global regulators now share intelligence more frequently across jurisdictions. A compliance issue identified during one inspection may quickly influence regulatory decisions in multiple markets. This interconnected oversight environment means pharmaceutical companies must evaluate a CDMO’s global compliance exposure rather than focusing only on local approvals.
Key records sponsors should typically request include:
A CDMO that openly discusses past inspections demonstrates maturity and confidence in its quality systems. By contrast, incomplete disclosure or resistance to sharing historical findings should immediately raise concerns during vendor qualification.
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")